• Anlotinib in Desmoplastic Small Round Cell Tumors

  2026-09-29

  This case report describes radiographic regression of metastatic intra-abdominal desmoplastic small round cell tumor after anlotinib treatment, followed by tolerable maintenance therapy. Its main contribution is hypothesis generation for a rare tumor with limited treatment standards, rather than proof of efficacy in a controlled clinical study.

• Native Protein Gel Electrophoresis with K4142

  2026-09-29

  Use native protein gel electrophoresis to separate acidic proteins while retaining structural features and, where compatible, biological activity. This practical workflow shows how K4142 supports enzyme assays, complex analysis, and protein purification while translating cancer-biology findings into carefully bounded biochemical experiments.

• Procainamide Hydrochloride: A Translational Bridge

  2026-09-28

  Procainamide Hydrochloride is more than a classical antiarrhythmic tool: it connects Nav1.5 biology, immune modulation, DNA methylation, and cisplatin response. This thought-leadership analysis shows how translational researchers can exploit that breadth while controlling for polypharmacology and preclinical limitations.

• KU-55933 for Telomere-Stress Assay Design

  2026-09-28

  Explore how KU-55933, an ATM kinase inhibitor, can help test whether ATM contributes to telomere-stress signaling and mitochondrial dysfunction. A recent telomere-recap study offers a distinct experimental framework for separating DNA-damage signaling from telomere-length effects.

• From Neutrophil Biology to Translational Stroke Design

  2026-09-27

  A mechanistic look at CKLF1-driven neutrophil infiltration after ischemic stroke—and a cautious framework for testing ICI 118,551 hydrochloride as an orthogonal pharmacological probe without implying a proven link to the reported pathway.

• Axitinib: From VEGFR Mechanism to Translational Evidence

  2026-09-26

  Axitinib (AG 013736) offers a potent way to perturb VEGFR signaling, but translating that perturbation into meaningful cancer biology requires more than a single viability endpoint. This article connects its mechanism to assay design, model interpretation, and translational decision-making.

• Trolox C3183 for Reliable Redox Assays

  2026-09-25

  Learn how Trolox (SKU C3183) can support oxidative injury, cell viability, and antioxidant assay workflows without treating cell-free radical scavenging as proof of cellular protection. Practical guidance covers controls, stock preparation, interpretation, and product selection.

• Firefly Luciferase mRNA: Workflow & FNP Insights

  2026-09-25

  Build a reproducible bioluminescent readout for transfection, expression, and cell-based delivery studies with a capped, 5-methoxyuridine-modified reporter. Learn how to use it to compare delivery conditions—and how to interpret the lung-targeted nanoparticle findings without confusing research formulation stability with the storage requirements of the mRNA itself.

• Cabamiquine: Fast Translation Block, Slow Clearance

  2026-09-24

  This study combines translation-sensitive assays, parasite growth measurements, and live-cell imaging to show that cabamiquine shuts down protein synthesis rapidly but kills Plasmodium falciparum more slowly. The difference helps explain why pharmacodynamic effects and parasite clearance in patients do not necessarily occur on the same timeline.

• Ibuprofen Assays: Separating Biology from Exposure

  2026-09-24

  Ibuprofen research can connect cyclooxygenase inhibition with cell phenotypes, but assay results also depend on how exposure and controls are handled. This guide uses a human serum albumin study of a different drug as a methodological lens—not as evidence about ibuprofen—to sharpen decisions in colon cancer research.

• AM251: Practical Guidance for CB1 and Viability Assays

  2026-09-24

  This scenario-driven guide explains how to use AM251 (SKU B1427) when interpreting cell viability, apoptosis, and cannabinoid-signaling experiments. It covers assay design, solvent and storage considerations, key limitations, and how to evaluate a reagent source without assuming that binding potency alone guarantees a reproducible cellular response.

• Viperin Targets Coronavirus nsp8 to Disrupt RTC

  2026-09-23

  A 2026 study identifies a nonenzymatic antiviral function of viperin: direct binding to coronavirus nsp8 disrupts replication-transcription complex assembly and reduces RNA-dependent RNA polymerase activity. Using porcine deltacoronavirus as a model, the work separates this mechanism from ddhCTP-mediated RNA synthesis interruption and suggests a conserved target for antiviral drug development.

• Exendin-4 Workflows for Beta Cell Research

  2026-09-22

  Build mechanism-first assays with Exendin-4 (Exenatide) to connect GLP-1 receptor activation with cAMP, insulin secretion, and proinsulin transcription. This workflow also shows how purified peptide benchmarking can inform yeast-based production studies, metabolic models, and troubleshooting decisions.

• Recombinant Mouse IFN-γ in MASH-HCC Assays

  2026-09-22

  Use Recombinant Mouse IFN-γ to test whether impaired antigen presentation in MASH-HCC cells is reversible, pathway-dependent, or intrinsically blocked. This workflow connects controlled cytokine stimulation with MHC-I, NLRC5, macrophage, T-cell, and antiviral bioactivity readouts.

• DFO, Ferroptosis and Translational Precision

  2026-09-21

  DFO is a powerful forensic fluorescence reagent, but its acronym can be confused with deferoxamine in biomedical research. This thought-leadership article connects the mechanistic discipline of latent fingerprint chemistry with findings from silver nanoparticle-induced ferroptosis in zebrafish, while defining the evidence and identity controls required for responsible translational use.

8610 records 1/574 page Next 12345 下5页 Last page